Proudly supported by Diabetes NSW & ACT and Diabetes Queensland.
Golimumab, which is available in Australia under the brand name Simponi for people with diseases such as rheumatoid arthritis, ulcerative colitis, psoriatic arthritis and ankylosing spondylitis, is an anti-tumor-necrosis-factor (TNF) therapy, which is generally administered subcutaneously, once per month, via a pre-filled syringe or through the SmartJect autoinjector.
Golimumab has now shown that it can also preserve beta-cell function in children and young adults with newly diagnosed Type 1 diabetes.
In a stage 2 study by a University at Buffalo, it was also demonstrated that golimumab reduced the amount of injected insulin required by children and young adults with newly diagnosed Type 1 diabetes by preserving their endogenous insulin production. Patients treated with golimumab had a higher C-peptide level at week 52 compared to placebo.
The findings were presented at the annual meeting of the American Diabetes Association.